← All trials
NCT05469490
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2022
- Primary completion
- Aug 31, 2024
- Completion date
- Dec 31, 2026
- First posted
- Jul 21, 2022
- Last posted
- Sep 30, 2022
- Enrollment
- 0
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of PittsburghLead sponsor
- University of PittsburghOverall official - principal investigator
- University of PittsburghReponsible party - principal investigator
- Lumos PharmaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.